OxiGene (OXGN +7.7%) says results of its Phase 2 trial of Zybrestat, a treatment for patients...

|By:, SA News Editor

OxiGene (OXGN +7.7%) says results of its Phase 2 trial of Zybrestat, a treatment for patients with polypoidal choroidal vasculopathy, suggest that the drug, even if administered only as a single dose intravenously, may produce a transient reduction in both polyp activity and amount of subretinal fluid in patients with disease. The company also notes that further clinical testing with a more practical topical formulation in combination with photodynamic therapy may be warranted for further testing.